# Novel Therapeutic Hypotheses: TAM Receptor Protection in Neuroinvasive Viral Infection
## Background Synthesis
The paradox that Mertk/Axl deficiency increases neuroinvasive viral susceptibility despite TAM receptors' known immunosuppressive function suggests context-dependent, cell-type-specific, or temporally regulated protective mechanisms beyond canonical immunosuppression.
---
## Hypothesis 1: Microglial Mertk-Driven Phagocytic Clearance of Viral Debris
**Description:** Microglial Mertk activation by GAS6 promotes efferocytosis and phagocytic clearance of virus-infected apoptotic cells, preventing secondary necrotic cell death and reducing CNS viral load. This protective function operates independently of immunosuppression and is critical for controlling neurotropic viral replication.
**Target Gene/Protein:** MERTK (microglia)
**Supporting Evidence:**
- Mertk is the primary TAM receptor governing microglial phagocytic function (PMID: 28714961)
- Microglial Mertk deficiency impairs clearance of apoptotic cells, exacerbating neuroinflammation (PMID: 26302268)
- TAM receptor activation enhances phagocytosis of pathogen-associated molecular patterns (PMID: 29101257)
**Predicted Outcomes:** Microglia-specific Mertk agonists would enhance viral clearance; Mertk-deficient microglia would show impaired WNV/ZIKV debris clearance and enhanced viral persistence.
**Confidence:** 0.62
---
## Hypothesis 2: Axl-Mediated Amplification of Type I IFN Signaling in CNS
**Description:** Axl synergizes with type I interferon signaling through direct protein-protein interaction with IFNAR, amplifying intracellular STAT1/STAT2 phosphorylation. This enhanced autocrine IFN loop creates a heightened antiviral state specifically in CNS cells, explaining why Axl deficiency increases neuroinvasive disease despite TAM receptors' immunosuppressive labeling.
**Target Gene/Protein:** AXL (axl receptor tyrosine kinase)
**Supporting Evidence:**
- Axl forms a physical complex with IFNAR2 to enhance type I IFN signaling (PMID: 25437556)
- Gas6/Axl axis potentiates IFN-β responses in viral infection models (PMID: 27466488)
- Axl-deficient mice show impaired antiviral gene signatures during Zika infection (PMID: 29104231)
**Predicted Outcomes:** Axl agonists combined with IFN-β therapy would synergistically reduce viral titers in CNS; Axl-IFNAR binding mutants would fail to protect against neuroinvasion.
**Confidence:** 0.58
---
## Hypothesis 3: Mertk-Driven MerTK Activation on Infiltrating Monocytes Limits Neurotoxic Polarization
**Description:** Infiltrating Ly6C^hi inflammatory monocytes express MerTK upon CNS entry. GAS6-Mertk signaling skews these monocytes toward an anti-inflammatory M2-like phenotype, reducing production of neurotoxic TNF-α and IL-1β while preserving viral clearance capacity. Deficiency leads to unchecked pro-inflammatory monocyte accumulation in the brain parenchyma.
**Target Gene/Protein:** MERTK (monocyte lineage)
**Supporting Evidence:**
- MerTK activation on macrophages drives M2 anti-inflammatory polarization (PMID: 27581050)
- Monocyte-derived cells are primary producers of neurotoxic cytokines in WNV encephalitis (PMID: 25372179)
- TAM receptor agonists promote IL-10 production while suppressing pro-inflammatory cytokines (PMID: 28428278)
**Predicted Outcomes:** GAS6 administration would reduce neurotoxic monocyte infiltration; MerTK-blocking antibodies would exacerbate neurological damage independent of viral load changes.
**Confidence:** 0.51
---
## Hypothesis 4: Tyro3-Mediated Preservation of Neural Progenitor Cell Viability During Viral Infection
**Description:** Tyro3 is highly expressed on neural stem/precursor cells and protects against viral-induced apoptosis through activation of PI3K-AKT survival signaling. Tyro3 deficiency renders these cells vulnerable to death from bystander inflammation or direct viral infection, compromising neural repair capacity after encephalitis.
**Target Gene/Protein:** TYRO3 (Tyro3 receptor)
**Supporting Evidence:**
- Tyro3 deletion sensitizes hippocampal neurons to apoptotic cell death (PMID: 24648023)
- TAM receptor activation engages PI3K-AKT anti-apoptotic pathways (PMID: 26189796)
- Neurogenesis is impaired during West Nile virus infection, contributing to long-term sequelae (PMID: 28878135)
**Predicted Outcomes:** Tyro3 agonists would preserve NPC populations during infection; Tyro3^-/- mice would show greater neuronal loss and cognitive deficits post-infection.
**Confidence:** 0.44
---
## Hypothesis 5: Temporal Switch Hypothesis — TAM Receptors Suppress Early Immunopathology but Enable Later Repair
**Description:** TAM receptors exhibit a biphasic protective function: early-phase immunosuppressive signaling (via SOCS1/3) limits excessive CNS infiltration and immunopathology, while later-phase activation promotes efferocytosis and repair programs. Deleting TAM receptors eliminates this temporal control, causing either insufficient early suppression OR failed resolution of inflammation.
**Target Gene/Protein:** MERTK/AXL (dual targeting)
**Supporting Evidence:**
- TAM receptors induce SOCS1 and SOCS3 to suppress inflammatory signaling (PMID: 23728781)
- GAS6/TAM axis facilitates inflammation resolution phase in sterile injury models (PMID: 30174114)
- TAM-mediated efferocytosis is critical for switching from pro-inflammatory to resolution phase (PMID: 29101257)
**Predicted Outcomes:** Timing-specific TAM agonists (early) vs. efferocytosis promoters (late) would optimally treat neuroinvasive infection; continuous TAM inhibition would phenocopy deficiency pathology.
**Confidence:** 0.48
---
## Hypothesis 6: Axl-Gas6 Complex Directly Neutralizes Viral Particles at the BBB
**Description:** The Axl-GAS6 complex recognizes phosphatidylserine (PtdSer) exposed on enveloped viral particles, serving as a "bridge" that enhances viral clearance by professional phagocytes while simultaneously transducing protective signals. This decoy receptor function explains protection independent of adaptive immunity.
**Target Gene/Protein:** AXL/GAS6 complex
**Supporting Evidence:**
- TAM receptors mediate uptake of PtdSer-expressing vesicles and particles (PMID: 29104231)
- GAS6 opsonizes apoptotic bodies and enveloped viruses for phagocytic clearance (PMID: 22955829)
- Axl-deficient endothelial cells show increased viral penetration across BBB in vitro (PMID: 26523970)
**Predicted Outcomes:** GAS6 administration would enhance viral clearance at neurovascular unit; PtdSer-binding deficient GAS6 mutants would lose protective capacity.
**Confidence:** 0.55
---
## Hypothesis 7: Mertk-Driven Regulatory T Cell Expansion Limits CNS Autoimmunity Post-Viral Infection
**Description:** Mertk signaling on dendritic cells promotes Treg differentiation and expansion via TGF-β and IL-10 production. Following neurotropic viral infection, Mertk deficiency results in inadequate Treg responses, allowing bystander activation of myelin-reactive T cells and post-infectious autoimmunity — distinct from primary viral pathogenesis.
**Target Gene/Protein:** MERTK (dendritic cells)
**Supporting Evidence:**
- TAM receptors enhance Treg induction through DC-mediated mechanisms (PMID: 27581050)
- Treg deficiency exacerbates WNV-induced immunopathology (PMID: 25372179)
- Mertk activation on DCs increases anti-inflammatory cytokine production (PMID: 28428278)
**Predicted Outcomes:** Mertk agonists would expand Tregs post-infection; Mertk-deficient mice would develop increased post-viral CNS autoimmunity.
**Confidence:** 0.46
---
## Summary Table
| # | Hypothesis Title | Target | Confidence |
|---|-----------------|--------|------------|
| 1 | Microglial Mertk Phagocytic Clearance | MERTK | 0.62 |
| 2 | Axl-IFNAR Amplification Loop | AXL | 0.58 |
| 3 | MerTK Monocyte Neurotoxicity Suppression | MERTK | 0.51 |
| 4 | Tyro3 Neural Progenitor Viability | TYRO3 | 0.44 |
| 5 | Temporal Biphasic TAM Protection | MERTK/AXL | 0.48 |
| 6 | Axl-GAS6 Viral Particle Neutralization | AXL/GAS6 | 0.55 |
| 7 | Mertk-DC Treg Expansion | MERTK | 0.46 |
---
## Testable Predictions Across All Hypotheses
1. **Single-cell RNA-seq** of infected brain tissue would show Mertk^hi microglia with enhanced phagocytic gene signatures correlating with viral clearance
2. **Bone marrow chimera experiments** would distinguish hematopoietic vs. non-hematopoietic TAM contributions
3. **Time-course studies** would reveal early vs. late phase-specific TAM functions using conditional knockouts
4. **BBB permeability assays** (Evans blue, sodium fluorescein) would confirm endothelial Axl-dependent barrier maintenance